NCT02654041View on ClinicalTrials.gov

Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Glioblastoma Multiforme (GBM)
Interventions
DRUG

Combined T3 and Methimazole treatment

Oral administration of T3 and Methimazole

Trial Locations (1)

64239

Tel-Aviv Medical Center, Israel, Tel Aviv

Sponsors
All Listed Sponsors
collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

lead

Musli Thyropeutics Ltd.

INDUSTRY

NCT02654041 - Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients | Biotech Hunter | Biotech Hunter